Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2018 1
2021 8
2022 8
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Casimersen.
[No authors listed] [No authors listed] 2022 Nov 29. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2022 Nov 29. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 36580568 Free Books & Documents. Review.
Casimersen is a synthetic antisense oligonucleotide designed to cause skipping of abnormal exons in the synthesis of the dystrophin gene and that is used to treat Duchenne muscular dystrophy. Casimersen has not been reported to cause ALT elevations during therapy an …
Casimersen is a synthetic antisense oligonucleotide designed to cause skipping of abnormal exons in the synthesis of the dystrophin g …
Casimersen: First Approval.
Shirley M. Shirley M. Drugs. 2021 May;81(7):875-879. doi: 10.1007/s40265-021-01512-2. Epub 2021 Apr 16. Drugs. 2021. PMID: 33861387 Review.
Casimersen received its first approval on 25 February 2021, in the USA, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. The approval, granted under the US FDA Accelerated Approval Program, was based o …
Casimersen received its first approval on 25 February 2021, in the USA, for the treatment of DMD in patients who have a confirmed mut …
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, Shieh PB. Wagner KR, et al. Muscle Nerve. 2021 Sep;64(3):285-292. doi: 10.1002/mus.27347. Epub 2021 Jun 29. Muscle Nerve. 2021. PMID: 34105177 Free PMC article. Clinical Trial.
RESULTS: Participants received casimersen for a mean 139.6 weeks. Treatment-emergent adverse events (TEAEs) occurred in all casimersen- and placebo-treated participants and were mostly mild (over 91.4%) and unrelated to casimersen or its dose. ...These result …
RESULTS: Participants received casimersen for a mean 139.6 weeks. Treatment-emergent adverse events (TEAEs) occurred in all casime …
Casimersen.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Jun 23;78(13):1149-1150. doi: 10.1093/ajhp/zxab138. Am J Health Syst Pharm. 2021. PMID: 33880492 No abstract available.
AMONDYS 45 (Casimersen), a Novel Antisense Phosphorodiamidate Morpholino Oligomer: Clinical Considerations for Treatment in Duchenne Muscular Dystrophy.
Vasterling ME, Maitski RJ, Davis BA, Barnes JE, Kelkar RA, Klapper RJ, Patel H, Ahmadzadeh S, Shekoohi S, Kaye AD, Varrassi G. Vasterling ME, et al. Cureus. 2023 Dec 28;15(12):e51237. doi: 10.7759/cureus.51237. eCollection 2023 Dec. Cureus. 2023. PMID: 38283433 Free PMC article. Review.
In a randomized double-blind trial, patients who received casimersen had significantly higher dystrophin levels when compared to those who received placebo. ...Based on the completed and ongoing clinical trials, casimersen has been well tolerated, with most adverse …
In a randomized double-blind trial, patients who received casimersen had significantly higher dystrophin levels when compared to thos …
Casimersen for Duchenne muscular dystrophy.
Wilton-Clark H, Yokota T. Wilton-Clark H, et al. Drugs Today (Barc). 2021 Dec;57(12):707-717. doi: 10.1358/dot.2021.57.12.3352740. Drugs Today (Barc). 2021. PMID: 34909800
In February 2021, Sarepta Therapeutics received accelerated Food and Drug Administration (FDA) approval for their new antisense oligonucleotide, casimersen (brand name Amondys 45). Casimersen targets exon 45 of the dystrophin gene and is expected to treat ~8% of the …
In February 2021, Sarepta Therapeutics received accelerated Food and Drug Administration (FDA) approval for their new antisense oligonucleot …
Casimersen (AMONDYS 45): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy.
Assefa M, Gepfert A, Zaheer M, Hum JM, Skinner BW. Assefa M, et al. Biomedicines. 2024 Apr 20;12(4):912. doi: 10.3390/biomedicines12040912. Biomedicines. 2024. PMID: 38672266 Free PMC article. Review.
Casimersen (AMONDYS 45(TM)) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta therapeutics. ...This article discusses the pathophysiology of DMD, summarizes available treatments thus far, and provides a full drug re …
Casimersen (AMONDYS 45(TM)) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarep …
Casimersen for the treatment of Duchenne muscular dystrophy.
Zakeri SE, Pradeep SP, Kasina V, Laddha AP, Manautou JE, Bahal R. Zakeri SE, et al. Trends Pharmacol Sci. 2022 Jul;43(7):607-608. doi: 10.1016/j.tips.2022.04.009. Epub 2022 May 14. Trends Pharmacol Sci. 2022. PMID: 35581038 No abstract available.
Advances in Dystrophinopathy Diagnosis and Therapy.
Saad FA, Siciliano G, Angelini C. Saad FA, et al. Biomolecules. 2023 Aug 28;13(9):1319. doi: 10.3390/biom13091319. Biomolecules. 2023. PMID: 37759719 Free PMC article. Review.
Other antisense oligonucleotide drugs in the pipeline include casimersen for exon 45, suvodirsen for exon 51, and golodirsen for exon 53 skipping. ...
Other antisense oligonucleotide drugs in the pipeline include casimersen for exon 45, suvodirsen for exon 51, and golodirsen for exon …
26 results